On April 04, 2016 Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, reported the publication of results from the dose escalation part of the Phase 1 clinical trial in the journal Lancet Oncology (Press release, Curis, APR 4, 2016, View Source [SID:1234510370]). Schedule your 30 min Free 1stOncology Demo! The publication, titled "Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial" was authored by the clinical investigators of the first-in-man Phase 1 study as well as members of Curis’ clinical and scientific teams. The publication is also accompanied by an independent commentary in the journal titled "Dual inhibition of oncogenic targets for B-cell malignancies" by Paul G. Richardson, M.D., R.J. Corman Professor of Medicine at the Jerome Lipper Multiple Myeloma Center at Dana Farber Cancer Institute.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The data from the Phase 1 monotherapy trial for CUDC-907, especially in heavily pretreated patients with relapsed/ refractory DLBCL are very encouraging and we look forward to data emerging from the current Phase 2 trial in patients with MYC-altered DLBCL," said Dr. Anas Younes, M.D., Chief of the Lymphoma Service of the Memorial Sloan Kettering Cancer Center in New York City, the Principal Investigator of the Phase 1 trial and the publication’s senior author.
Based on the clinical activity observed in patients with relapsed/ refractory-DLBCL, particularly those with cancers harboring MYC alterations, Curis has initiated a Phase 2 trial to evaluate CUDC-907 in patients with MYC-altered RR-DLBCL. Additional details of the Phase 2 trial can be found at www.clinicaltrials.gov (study identifier: NCT02674750)
About CUDC-907:
CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. Specifically, CUDC-907 is designed to inhibit HDACs 1, 2, 3, 6 and 10 and PI3K-alpha, delta and beta isoforms. CUDC-907 is being investigated in clinical studies in patients with lymphomas and advanced solid tumors. The development of CUDC-907 has been supported in part by The Leukemia & Lymphoma Society (LLS) under a funding agreement established in 2011 between Curis and LLS’s Therapy Acceleration Program.